About - Dr. Jing Pan
Dr. Jing Pan is a highly distinguished Chief Physician, internationally recognized immunology researcher, and leading expert in hematology and hemato-oncology practicing at Beijing GoBroad Hospital in Beijing, China. With over 13 years of extensive clinical experience, Dr. Pan has established herself as a pioneer and key contributor to the development, clinical translation, and optimization of CAR-T cell therapy in China. Holding dual doctoral training in clinical medicine and basic immunology, she seamlessly bridges the gap between laboratory research and cutting-edge patient care, bringing newfound hope to patients suffering from complex blood cancers and severe hematologic malignancies.
Currently serving as the Director of the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital, Dr. Pan’s clinical and research focus revolves around the most challenging cases of relapsed and refractory acute lymphoblastic leukemia (r/r ALL). Her groundbreaking work in donor-derived CD7 CAR-T strategies and sequential CAR-T therapies has drastically improved long-term patient outcomes, earning her the prestigious title of "Leading Talent in Medical and Health Science and Technology Innovation" under the Chinese Academy of Medical Sciences.
Key Stats & Information
- Years of Experience: 13+ Years
- Languages Spoken: English, Chinese
- Board Certification: Chief Physician, MD, PhD (Immunology)
- Hospital Privileges: Beijing GoBroad Hospital, Institute of Hematology & Blood Diseases Hospital
- Accepting New Patients: Yes
- Primary Specialization: Hemato-Oncology, CAR-T Cell Therapy, & Immunotherapy
Medical Expertise & Specializations
Dr. Jing Pan’s medical expertise is deeply rooted in her extensive dual-doctoral background, allowing her to approach complex hematologic diseases from both a clinical and fundamental immunological perspective. As a highly sought-after hemato-oncologist, her primary clinical focus is on relapsed/refractory (r/r) acute lymphoblastic leukemia, specifically B-cell (B-ALL) and T-cell (T-ALL/LBL) variations. These aggressive blood cancers present significant treatment hurdles, especially when standard chemotherapy and initial interventions fail. Dr. Pan’s innovative translational research provides lifelines to these patients through highly specialized immunotherapy protocols.
Her unparalleled contribution to the field involves pioneering donor-derived CD7 CAR-T strategies specifically tailored for r/r T-ALL. By addressing the major clinical challenges of post-treatment relapse and complex antigen escape, she subsequently developed a novel dual-epitope CD5 CAR-T strategy. For B-ALL patients, Dr. Pan has successfully optimized a sequential CD19/CD22 CAR-T therapy, heavily reducing the chances of tumor immune evasion and vastly improving the long-term survival and remission rates of her patients. Her holistic management covers the entirety of the treatment spectrum, including precision diagnostics, bridging to hematopoietic stem cell transplantation (HSCT), and the critical management of therapy-related toxicities.
Conditions Treated
- Relapsed/Refractory Acute Lymphoblastic Leukemia (r/r B-ALL): Comprehensive management and targeted immunotherapy for advanced B-cell leukemia that has resisted traditional interventions.
- Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (r/r T-ALL/LBL): Specialized care using cutting-edge CD7 and CD5 CAR-T strategies.
- Leukemia & Lymphoma: Broad-spectrum diagnostics and precision treatment planning for various forms of blood cancers and malignancies.
- Multiple Myeloma & Hematologic Malignancies: Advanced therapeutic protocols for plasma cell neoplasms and bone marrow disorders.
- Extramedullary Disease: Management of complex leukemia cases where the disease has spread outside the bone marrow, presenting bulky tumor masses.
- Autoimmune Diseases: Utilizing state-of-the-art CAR-T cellular therapy to target and reset malfunctioning immune responses in severe autoimmune conditions.
Procedures Performed
- CAR-T Cell Therapy Infusions: Administration of autologous and donor-derived CAR-T cells, including CD19, CD22, CD7, and dual-epitope CD5 formulations.
- Hematopoietic Stem Cell Transplantation (HSCT) Bridging: Coordinating the critical timing and integration of CAR-T therapy as a bridge to curative allogeneic stem cell transplants.
- Precision Hematologic Diagnosis: Stratified, biomarker-driven diagnostic evaluations to determine the most effective personalized immunotherapy path.
- Toxicity Management (CRS/ICANS): Expert clinical intervention to monitor, manage, and mitigate Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome.
- Long-Term Efficacy Monitoring: Ongoing molecular and cellular tracking post-infusion to ensure durable remission and swiftly address any signs of antigen escape or relapse.
Education, Training & Academic Achievements
Dr. Jing Pan’s foundational medical excellence is built upon rigorous dual doctoral training, culminating in an MD and a PhD in Immunology. Her academic prominence is highlighted by her role as a Tenure-Track Associate Professor and PhD Supervisor at the esteemed Peking Union Medical College, Chinese Academy of Medical Sciences. She also serves as Chief Physician at the National Key Laboratory of Blood Science, Institute of Hematology & Blood Diseases Hospital.
An internationally lauded researcher, Dr. Pan’s clinical breakthroughs have been published in the world's most prestigious medical journals. She serves as the first or corresponding author for pivotal studies featured in Lancet Oncology, the Journal of Clinical Oncology (JCO), and Nature Medicine. With four ESI Highly Cited Papers to her name, her clinical protocols and research findings have directly shaped global oncology standards, being incorporated into six national and international clinical guidelines.
She regularly presents her team's cutting-edge findings at premier global oncology and hematology symposiums, including ASCO (where her Phase I donor-derived CD7 CAR-T study was a Highlight Abstract), ASH, EHA, and JSH. In recognition of her transformative impact on patient survival rates and hemato-oncology innovation, her work has been selected twice as one of the "Top 10 Advances in Hematology in China."
Frequently Asked Questions (FAQ)
What is Dr. Jing Pan's primary medical specialty?
Dr. Jing Pan is a highly specialized hemato-oncologist and immunologist focusing on the treatment of complex hematologic malignancies. Her primary medical specialty is the application, optimization, and clinical translation of CAR-T cell therapy for severe blood cancers, particularly relapsed/refractory acute lymphoblastic leukemia (r/r B-ALL and T-ALL), lymphoma, multiple myeloma, and advanced autoimmune diseases.
Where does Dr. Jing Pan practice and treat patients?
Dr. Pan serves as the Director of the Department of Hemato-Oncology & Immunotherapy at Beijing GoBroad Hospital in Beijing, China. Additionally, she holds the position of Chief Physician at the Institute of Hematology & Blood Diseases Hospital, under the Chinese Academy of Medical Sciences, giving her access to state-of-the-art national key laboratories and advanced clinical research facilities.
Why is Dr. Pan considered an expert in CAR-T cell therapy?
With over 13 years of clinical experience and a dual MD/PhD in Immunology, Dr. Pan is a recognized pioneer in immunotherapy. She developed the critical donor-derived CD7 CAR-T strategy for T-ALL, advanced sequential CD19/CD22 therapies for B-ALL, and engineered dual-epitope CD5 CAR-T protocols to prevent tumor antigen escape. Her clinical trials have consistently yielded high remission rates for patients who previously had no viable treatment options.
What was the significance of Dr. Pan's Phase II clinical trial for CAR-T therapy?
Dr. Pan’s Phase II trial successfully expanded upon safety evaluations to prove real-world clinical efficacy for donor-derived CD7 CAR-T therapy. Recognizing that bulky extramedullary disease takes longer to show remission, she innovatively adjusted clinical endpoints to measure the "best overall response (BOR) within 3 months," more accurately capturing the profound, life-saving dynamic of this therapy, especially for patients bridging to an allo-HSCT.
How does Dr. Pan manage relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)?
To combat the high risk of relapse and immune evasion common in advanced B-ALL, Dr. Pan optimizes a sequential CD19/CD22 CAR-T strategy. By targeting multiple malignant antigens in succession, this highly targeted approach significantly reduces the chance of the cancer mutating to hide from the engineered T-cells, thereby vastly improving long-term survival outcomes and maintaining deep molecular remission.
Can Dr. Jing Pan treat patients with extramedullary leukemia?
Yes, Dr. Pan possesses specialized expertise in managing extramedullary disease—a complex condition where leukemia cells form tumors outside the bone marrow. Her recent expanded clinical trials actively included higher proportions of patients with these bulky extramedullary lesions, proving that appropriately timed and monitored CAR-T therapy can achieve deep remission even in these highly challenging, non-traditional cancer presentations.
How are the side effects of CAR-T cell therapy handled under her care?
Immunotherapy can trigger severe immune responses, notably Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Dr. Pan is a renowned specialist in the stratified risk assessment and acute medical management of these CAR-T–related toxicities. Her clinical protocols prioritize patient safety through vigilant post-infusion monitoring and rapid pharmacological intervention to neutralize severe side effects without compromising the therapy's anti-tumor efficacy.
Does Dr. Jing Pan treat autoimmune diseases?
Yes. While globally recognized for her work in hematologic oncology, Dr. Pan also applies advanced CAR-T cell therapy to the treatment of severe, refractory autoimmune diseases. By utilizing engineered immune cells to target and eliminate the specific rogue B-cells or immune pathways responsible for autoimmune attacks, her immunotherapy protocols offer a revolutionary "immune reset" for patients suffering from debilitating autoimmune conditions.
What role does bone marrow transplant (HSCT) play in her treatments?
For many high-risk patients, CAR-T cell therapy acts as a critical "bridge" to a curative allogeneic hematopoietic stem cell transplantation (allo-HSCT). Dr. Pan expertly integrates CAR-T infusions to rapidly induce a deep clinical remission, reducing the tumor burden to undetectable levels. This meticulously timed remission provides the optimal, safe window required to proceed with a successful bone marrow transplant, securing a permanent cure.
How widely recognized is Dr. Pan’s medical research?
Dr. Pan’s research is globally recognized at the highest levels of oncology. Her clinical breakthrough studies have been published in top-tier journals such as Nature Medicine, Lancet Oncology, and the Journal of Clinical Oncology. Furthermore, her clinical findings are directly incorporated into six major national and international treatment guidelines, fundamentally changing how hematologists worldwide approach refractory leukemia.
Ready to Transform Your Life with Dr. Jing Pan?
Going on a complex medical journey is a significant decision, and choosing the right world-class specialist is the first and most crucial step toward a healthier future. PlacidWay partners with top-tier medical professionals globally, like Dr. Jing Pan, to provide you with seamless, stress-free access to groundbreaking hematology and immunology care.
Contact PlacidWay today to schedule your initial consultation with Dr. Jing Pan, receive a comprehensive personalized medical quote, and learn more about navigating advanced CAR-T immunotherapy and medical travel to Beijing. Let our dedicated team handle the complex logistical details so you can focus entirely on your healing and transformation.
Important Disclaimer
PlacidWay.com provides medical travel information, not healthcare services. We don't endorse any providers, and we're not responsible for the care you receive.
Pricing: Prices on our site are estimates only, provided by the centers. Always confirm actual prices directly with the provider before booking to ensure full transparency and avoid hidden fees.
Your Health: Consult your local licensed healthcare provider before pursuing any treatment found on our site. Your health decisions are your responsibility.
Share this listing